Showing results (461-470 of 525) with videos related to
Sort By:
Pageof 53
The Journal of Experimental Medicine|October 12, 2011
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedHua-Xin Liao, Xi Chen, Supriya Munshaw, et al.The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.The Lancet. Infectious Diseases|September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trialFlonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.Journal of Medicinal Chemistry|June 13, 2013
Pyridone-conjugated monobactam antibiotics with gram-negative activityMatthew F Brown, Mark J Mitton-Fry, Joel T Arcari, et al.Pageof 53